Pages that link to "Q3167165"
Jump to navigation
Jump to search
The following pages link to Jean-Luc Harousseau (Q3167165):
Displaying 50 items.
- François Fillon (Q101410) (← links)
- Jacques Auxiette (Q1677884) (← links)
- Haute autorité de santé (Q3128526) (← links)
- Prognostic significance of copy-number alterations in multiple myeloma (Q24643402) (← links)
- Comparison of 200 mg/m(2) melphalan and 8 Gy total body irradiation plus 140 mg/m(2) melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergrou (Q33340726) (← links)
- Safety and efficacy of bortezomib in high-risk and elderly patients with relapsed multiple myeloma (Q33374964) (← links)
- Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma (Q33377526) (← links)
- Characterisation of haematological profiles and low risk of thromboembolic events with bortezomib in patients with relapsed multiple myeloma (Q33380816) (← links)
- Elotuzumab in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myeloma (Q33401018) (← links)
- Superiority of the triple combination of bortezomib-thalidomide-dexamethasone over the dual combination of thalidomide-dexamethasone in patients with multiple myeloma progressing or relapsing after autologous transplantation: the MMVAR/IFM 2005-04 R (Q33401216) (← links)
- Monoclonal gammopathy of undetermined significance: a consensus statement (Q34117717) (← links)
- Gene expression profiling of multiple myeloma reveals molecular portraits in relation to the pathogenesis of the disease (Q34182154) (← links)
- Mutations in TP53 are exclusively associated with del(17p) in multiple myeloma (Q34255215) (← links)
- The relationship between quality of response and clinical benefit for patients treated on the bortezomib arm of the international, randomized, phase 3 APEX trial in relapsed multiple myeloma (Q34595043) (← links)
- Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guideline (Q34603644) (← links)
- Myeloma in patients younger than age 50 years presents with more favorable features and shows better survival: an analysis of 10 549 patients from the International Myeloma Working Group (Q34656801) (← links)
- Combination of international scoring system 3, high lactate dehydrogenase, and t(4;14) and/or del(17p) identifies patients with multiple myeloma (MM) treated with front-line autologous stem-cell transplantation at high risk of early MM progression-r (Q35180069) (← links)
- Stem-cell transplantation in multiple myeloma (Q36199179) (← links)
- Chromosomal abnormalities are major prognostic factors in elderly patients with multiple myeloma: the intergroupe francophone du myélome experience (Q37033951) (← links)
- Thalidomide for treatment of multiple myeloma: 10 years later (Q37075738) (← links)
- Individualizing treatment of patients with myeloma in the era of novel agents. (Q37143728) (← links)
- Lenalidomide in combination with dexamethasone for the treatment of relapsed or refractory multiple myeloma (Q37262033) (← links)
- Current multiple myeloma treatment strategies with novel agents: a European perspective (Q37677935) (← links)
- Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the International Myeloma Working Group (Q37801221) (← links)
- Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. (Q37835571) (← links)
- Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2. (Q37835572) (← links)
- Multiple myeloma treatment strategies with novel agents in 2011: a European perspective (Q37858327) (← links)
- Firstline treatment and maintenance in newly diagnosed multiple myeloma patients. (Q37867566) (← links)
- Monoclonal antibodies in the treatment of multiple myeloma (Q37903377) (← links)
- Comparison of serum free light chain and urine electrophoresis for the detection of the light chain component of monoclonal immunoglobulins in light chain and intact immunoglobulin multiple myeloma (Q38398899) (← links)
- International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma (Q38832525) (← links)
- Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma. (Q38852886) (← links)
- High rates of durable responses with anti-CD22 fractionated radioimmunotherapy: results of a multicenter, phase I/II study in non-Hodgkin's lymphoma (Q39857869) (← links)
- VEGF induces Mcl-1 up-regulation and protects multiple myeloma cells against apoptosis (Q40541706) (← links)
- Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial. (Q42914716) (← links)
- Lenalidomide in combination with melphalan and dexamethasone in patients with newly diagnosed AL amyloidosis: a multicenter phase 1/2 dose-escalation study (Q42931881) (← links)
- Bortezomib plus dexamethasone induction improves outcome of patients with t(4;14) myeloma but not outcome of patients with del(17p). (Q42965343) (← links)
- Superior outcomes associated with complete response in newly diagnosed multiple myeloma patients treated with nonintensive therapy: analysis of the phase 3 VISTA study of bortezomib plus melphalan-prednisone versus melphalan-prednisone (Q42971327) (← links)
- Prognostic impact of 18F-fluoro-deoxyglucose positron emission tomography in untreated mantle cell lymphoma: a retrospective study from the GOELAMS group. (Q43080849) (← links)
- Bortezomib and high-dose melphalan as conditioning regimen before autologous stem cell transplantation in patients with de novo multiple myeloma: a phase 2 study of the Intergroupe Francophone du Myelome (IFM). (Q43250016) (← links)
- Impact of prior therapies on the relative efficacy of bortezomib compared with dexamethasone in patients with relapsed/refractory multiple myeloma (Q43281992) (← links)
- Thalidomide in patients with advanced multiple myeloma: a study of 83 patients--report of the Intergroupe Francophone du Myélome (IFM). (Q44078511) (← links)
- Translocation t(14;16) and multiple myeloma: is it really an independent prognostic factor? (Q45738627) (← links)
- Analysis of herpes zoster events among bortezomib-treated patients in the phase III APEX study (Q46423653) (← links)
- Bortezomib or high-dose dexamethasone for relapsed multiple myeloma (Q46549268) (← links)
- Evaluation of response to fractionated radioimmunotherapy with 90Y-epratuzumab in non-Hodgkin's lymphoma by 18F-fluorodeoxyglucose positron emission tomography (Q46758798) (← links)
- Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myélome. (Q53243787) (← links)
- Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma (Q57151125) (← links)
- Effects of Lenalidomide and Dexamethasone Treatment Duration on Survival in Patients With Relapsed or Refractory Multiple Myeloma Treated With Lenalidomide and Dexamethasone (Q57904548) (← links)
- Lenalidomide Maintenance after Stem-Cell Transplantation for Multiple Myeloma (Q58415969) (← links)